Company Profile · Healthcare

Abbott Laboratories

ABT · US
Exchange
US
Country
USA
IPO date
Jan 13, 1978
Employees
122,000
Current Price
$88.41
Live · Jun 18, 2026
Baillie Growth Score
47/100
Weak
Intrinsic Value · Three-Tier Range Current price $88.41 Live · Between the conservative and fair ranges

Composite valuation range · conservative $70–$85 / fair $90–$105 / optimistic $115–$135. At $88.41, Between the conservative and fair ranges.

At publication $88.38 (May 21, 2026)

No reports on this stock in your language yet.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Market cap$154.15B
Revenue (TTM)$45.13B
EBITDA$11.74B
Profit margin13.9%
ROE12.33%
P/E (TTM)24.79
Forward P/E16.53
PEG1.34
EPS$3.57
Dividend yield2.69%
52-week range$81.97 – $136.28
Analyst target$116.54
Analyst rating4.3 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.